• HELP
  • FAQs
  • INTRANET

Uganda Virus Research Institute

REPUBLIC OF UGANDA

Conference On Innovations In Tuberculosis 2024

TB conference poster on abstracts

Tuberculosis (TB) caused 1.6 million deaths in 2021, being the leading cause of death among infectious diseases, above HIV. Yet, it is a curable and preventable disease. While a quarter of the global population has been infected, only 5-10 % of infected individuals develop symptoms. The highest burden regions are South-East Asia, Africa, and the Western Pacific. This bacterial disease is treated by a long course of antibiotics. Nevertheless, for Multidrug-resistant TB (MDR-TB) treatment options are limited, and MDR-TB remains a public health crisis and a health security threat.

TB is a priority on the global health agenda. Orchestrated actions of national and global leadership, researcher organizations, and civil societies strive to achieve a world free of TB. Towards this goal, equitable access to prevention, testing, treatment, and care remains a challenge. On the other hand, we are witnessing encouraging new tools to curb TB. A recent study demonstrated a remarkable reduction in TB transmission due to nutritional supplements offered to household contacts, providing an evidence-based approach to intervene with structural determinants of TB, such as malnutrition. On the biomedical side, a historical milestone seems to be within close range, with the late-stage clinical evaluation of a vaccine to prevent a pulmonary form of TB in adolescents and adults, developed by the Gates Foundation. In parallel, new treatment guidelines on 6-month all-oral regimens for MDR-TB offer simplified treatment options for those patients.

Yet these exciting developments and innovations are mainly discussed at major international meetings. This, in turn, offers limited space for researchers and healthcare professionals from high-burden countries in Africa, and restricts discussions tailored to regional epidemiological situations, healthcare, and societal contexts. To this end, we propose a platform to disseminate clinically relevant innovations and discuss their translation and implementation in Africa, considering region-specific epidemic patterns, available prevention, testing and treatment options, and healthcare settings.

Registration

Standard Registration Deadline: Wednesday, 19 June 2024 23:59 CE Register Here

Fees and Conditions

 

Academia

 

 RLS

 

Industry

 

Local

HCP

Early Fee (payment before/on 23 February 2024) 

€200

€100

€750

€30

Regular Fee (payment before/on 20 June 2024)

€300

€150

€950

€40

Onsite Fee  (payment before/on 1 July 2024)

€350

€200

€1000

€50

 

Fee Waivers

 

NGO Representatives / Government Representatives (i.e. MOH, NIH, NIAID, etc.) / Advocates

50% Off Current Regular Fee

Members of Endorsers  

25% Off Current Regular Fee

Sponsors 

Contact Secretariat 

 

If you are eligible for a discount, please contact the conference secretariat Yulia Veldhuis at yulia.veldhuis@amededu.com for the special registration code.

*Countries included in the low-income and middle-income economies list of the World Bank Classification

Important
  • We strongly advise that you register early to ensure your registration. Registration will close when the capacity of the venue is reached.

  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

 

The Abstract Submission Portal is now open! Submit 

Abstract Submission Deadline: Friday, 12 April at 23:59 EAT

Abstracts
  • The Conference on Innovations in Tuberculosis accepts new original data as well as encored abstracts. All abstracts must focus on the African region and contain up-to-date information at the time of the conference. 
  • Registration fees are waived for early-career professionals with an accepted abstract. A 50% discount is offered to early-career professionals without an accepted abstract.The requirements for the application are specified here.
  • Abstract submitters are strongly encouraged to use person-first language in their abstracts. View the video tutorial and guidelines here.
Terms and Conditions

By submitting an abstract to a meeting organized by Virology Education BV (VE), the abstract submitter hereby agrees to the terms and conditions.

The terms and conditions can be viewed here.